Basel, Switzerland (ots/PRNewswire) - - Roche Medicines Offer Improved Ways of Fighting the Leading Cause of Cancer Death in Women New data being presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) show that Herceptin (trastuzumab), Avastin (bevacizumab) and oral Xeloda (capecitabine) ...
London (ots/PRNewswire) - Platts -- The 13 members of the Organization of the Petroleum Exporting Countries (OPEC) pumped an average 31.38 million barrels per day (b/d) of crude oil in November, according to a Platts survey of OPEC and oil industry officials just released. This is a decline of 880,000 from the October level of 32.26 million b/d. Excluding ...
Basel, Switzerland (ots/PRNewswire) - - For non-US and non-UK Media Only - Long-term Results From a Phase III Study Highlight the Beneficial Role of MabThera in Patients With Recurrent or Resistant Disease Data presented at the 50th Annual Meeting of the American Society of Hematology (ASH) today ...
Toronto (ots/PRNewswire) - As economies around the world slow or worsen, the travel market is also expected to take a hit as fewer people may be traveling this year. Here are some traveling tips to save you time and money. 1. During this recession there are many discounts and deals to be found as companies and venues struggle to attract customers. Use http://www.RoadTripHelper.com, a price comparison ...
European Wind Energy Association (EWEA)
Brussels (ots/PRNewswire) - For the European Wind Energy Association (EWEA), the Renewable Energy Directive, agreed today, confirms Europe as the leader of the energy revolution the world needs. The target means that more than one third of EU electricity must come from renewables in 2020 and wind energy will be the biggest contributor. Moreover, the directive addresses existing barriers that prevent Europe from fully ...
Beerse, Belgium (ots/PRNewswire) - - Preliminary Phase II Re-treatment Results and two new Analyses From Phase III VISTA Presented at ASH Annual Meeting Janssen-Cilag today announced preliminary results from a prospective, international, multicenter, open-label, phase II study showing re-treatment with ...
Huntington Beach, California and Amsterdam (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading Agendia and the Netherlands Cancer Institute researchers will present data from multiple studies at the 2008 San Antonio Breast Cancer Symposium (SABCS) and ...
Basel, Switzerland (ots/PRNewswire) - - For Non-US Media Only - Abstract 234 - Roche and GlycArt Showcase Promising Early Results for its Next-Generation Lymphoma Treatment, R7159/GA101 Data presented for the first time today, at the 50th Annual Meeting of the American Society of Hematology (ASH), ...
Basel, Switzerland (ots/PRNewswire) - - For Non-US and Non-UK Media Only - Abstract Number: 1 - New Phase III Data Suggest Potential Role for MabThera in Treating Blood Disorder New data presented at the 50th Annual Meeting of the American Society of Hematology (ASH) today, show that people living ...
Basel, Switzerland (ots/PRNewswire) - - For Non-US and Non-UK Media BASEL, Switzerland, December 6 /PRNewswire/ -- - Abstract Numbers: 325 & LBA-1 BASEL, Switzerland, December 6 /PRNewswire/ -- - Pivotal Phase III Results Suggest MabThera is Set to Change the Face of Chronic Lymphocytic Leukaemia ...
Shanghai, China (ots/PRNewswire) - - Sales and design center dedicated to servicing mainland China Atmel(R) Corporation (Nasdaq: ATML) a leader in microcontroller based solutions announced today the grand opening of its new location in Shanghai, China. As a part of extending Atmel's commitment to ...
Maidenhead, England (ots/PRNewswire) - - New Data Add to the Body of Evidence That Show That Enbrel (Etanercept) Clears Skin and Can Sustain This Efficacy Over Time New data presented today at the 'Gene to Clinic' meeting taking place at the Royal College of Physicians in London, England, reinforce ...
Basel (ots/PRNewswire) - - Pegasys is the First and Only Pegylated Interferon to be Approved for Treatment of up to 72 Weeks in Treatment-Experienced Patients Roche announced today that the European Commission has approved Pegasys(R) (peginterferon alfa-2a (0 KD)) plus Copegus(R) (ribavirin) for the ...
Collegeville, Pennsylvania (ots/PRNewswire) - - Approval sought for investigational vaccine for protection against the 13 most prevalent serotypes associated with serious pneumococcal disease Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has submitted a marketing ...
Cork, Ireland (ots/PRNewswire) - - For Medical Media Only - PREZISTA now Indicated for the Broad Range of Treatment-Experienced Patients in the 27 EU Member States Tibotec Pharmaceuticals announced today that the European Commission adopted the decision to broaden the indication for PREZISTA(R) ...
Vancouver, and Paris (ots/PRNewswire) - - Combination Will Create a Global Leader in Wireless Data - Sierra Wireless to Make an all Cash Offer of EUR8.50 per Ordinary Share of Wavecom - Founders of Wavecom, Representing 21% of Wavecom's Shares Outstanding, Have Committed to Tender all Their Shares to the Offer - The Combination of Both Firms Uniquely Positioned to Benefit from the ...
Calgary, Canada (ots/PRNewswire) - Shelton Canada Corp.("Shelton" or the "Company") (TSXV symbol "STO") is pleased to announce record consolidated revenue from operations of CDN$4.548 million for three months ending Sept 30, 2008 and CDN$9.178 million for the nine months then ended as compared to CDN$1.086 million and CDN$1.129 million from continued operations for the three and nine months ending August 31, 2007. ...
Cork, Ireland, November 27 (ots/PRNewswire) - The Committee for Human Medicinal Products (CHMP) has issued a positive opinion recommending approval for once-daily dosing of 800 mg PREZISTA(R) (darunavir) with low-dose ritonavir as part of combination therapy in treatment-naïve adults (those who have never taken ...
Hamilton, Bermuda, November 27 (ots/PRNewswire) - - Schumacher-The Ultimate Designated Driver-Promotes Drinking and Driving Don't Mix at http://www.championsdrinkresponsibly.com Bacardi Limited, as part of its responsible drinking "Champions Drink Responsibly" campaign, is providing the drive of a lifetime - the opportunity to be in the passenger seat next ...
Abbotsford, Canada, November 24 (ots/PRNewswire) - ICS Copper Systems Ltd. (ICX:TSX.V) is continuing to advance the Mokambo project EMEW plant toward production of third party ore. To this end the Company is negotiating with ZESCO, Zambia's largest power utility to install a 4.2 kilometre 11 kV three phase powerline to ICS's EMEW plant and compound. This will provide the necessary and cost effective power to operate ...
Moscow, November 24 (ots/PRNewswire) - Platts, a leading global provider of energy and commodities information and a division of The McGraw-Hill Companies (NYSE: MHP), today announced it is joining forces with Interfax Information Services Group, a leading source of real-time business news from Russia and the ...
Basel, Switzerland, November 24 (ots/PRNewswire) - FOR NON-UK MEDIA DISTRIBUTION ONLY - Two Phase III Studies to be Presented at World's Major Hematology Meeting Prove MabThera's Benefits in Treating Chronic Lymphocytic Leukemia (CLL) Roche announced today that full results of the pivotal REACH trial ...
Beerse, Belgium, November 21 (ots/PRNewswire) - - European Authority Recommends Approval of ZEVTERA(TM) BEERSE, Belgium, November 21 /PRNewswire/ -- - A Broad-spectrum, Anti-MRSA Cephalosporin Antibiotic to Treat Complicated Skin and Soft Tissue Infections BEERSE, Belgium, November 21 /PRNewswire/ -- The Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the antibiotic, ...
Maidenhead, England, November 21 (ots/PRNewswire) - - Not for UK Journalists The European Committee for Medicinal Products for Human Use (CHMP) today announced its positive recommendation for the approval of Enbrel(R) (etanercept) as a treatment for children aged 8 years and over and adolescents with ...
Beerse, Belgium, November 21 (ots/PRNewswire) - Janssen-Cilag announced today that ustekinumab, the first in a new class of biologics, has received a positive opinion for the treatment of moderate to severe plaque psoriasis from the European Committee for Medical Products for Human Use (CHMP). This positive ...
San Diego, November 21 (ots/PRNewswire) - - New, CE-Marked Molecular Assay May Help Identify Women with Cervical Cancer or Pre-Cancer More Accurately than Competing Technologies, Studies Show - Gen-Probe's (Nasdaq: GPRO) CE-marked APTIMA(R) HPV assay may be an important new molecular tool to more ...
London, November 20 (ots/PRNewswire) - - Intel(R) Health Guide is the First Product in a Series Designed to Enable More Personalised Care Management for Chronic and Age-related Conditions Intel Corporation today announced the Intel(R) Health Guide, a care management tool designed for healthcare ...
Cork, Ireland, November 20 (ots/PRNewswire) - - Nearly 90 Percent of Patients Achieve Undetectable Viral Load in Phase IIa Trial Within 28 Days of Combined Treatment With Standard of Care New clinical data demonstrate the safety and antiviral activity of TMC435, an investigational protease inhibitor (PI) ...
Cork, Ireland, November 20 (ots/PRNewswire) - - Telaprevir Data Presented at AASLD Tibotec BVBA today announced that it has begun enrolling patients in its phase III study of telaprevir (VX-950), an investigational protease inhibitor (PI), in patients with chronic genotype 1 hepatitis C virus (HCV) for ...
Stockholm, November 20 (ots/PRNewswire) - Karolinska Development AB, have launched a new share issue up to a value of 147 million Swedish Kronor, (19 million USD) which has opened with a strong start to sales. To view the Multimedia News Release, please click: http://www.prnewswire.com/mnr/karolinskadevelopment/36025/ "We are very excited to have such ...